Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback